Literature DB >> 7387147

Effect of trimethoprim and trimethoprim-sulfamethoxazole on development of drug-resistant vaginal and fecal floras.

S J Pancoast, D M Hyams, H C Neu.   

Abstract

Trimethoprim-sulfamethoxazole (TMP-SMX) or trimethoprim (TMP) alone was given on a random double-blind basis to 26 young women to treat urinary tract infections. Fecal and introital aerobic bacterial floras were identified at 1, 7, 14, and 42 days to analyze changes in these floras or development of resistance to TMP or TM-SMX. Neither TMP alone nor the TMP-SMX combination administered for 2 weeks selected a resistant fecal or introital flora. In the few individuals who had strains resistant to TMP or TMP-SMX before initiation of therapy, these organisms did not persist once therapy began. Both programs effectively cleared the introitus and rectal areas of Enterobacteriaceae. Concentrations of TMP adequate to inhibit the majority of Escherichia coli strains causing urinary tract infections were found in the vaginal secretions.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387147      PMCID: PMC283769          DOI: 10.1128/AAC.17.2.263

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Trimethoprim R factors in enterobacteria from clinical specimens.

Authors:  R S Jobanputra; N Datta
Journal:  J Med Microbiol       Date:  1974-05       Impact factor: 2.472

2.  Synergistic activity of trimethoprim-sulfamethoxazole on gram-negative bacilli: observations in vitro and in vivo.

Authors:  J F Acar; F Goldstein; Y A Chabbert
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

3.  The effect of a combined preparation of trimethoprim and sulphamethoxazole following short-term and long-term administration on the flora of the human gut.

Authors:  H Knothe
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

4.  [Antibacterial activity of the combination trimethoprim-sulfamethoxazole compared with antibiotics].

Authors:  E Böhni
Journal:  Schweiz Med Wochenschr       Date:  1969-10-18

5.  Long-term treatment of persistent or recurrent urinary tract infection with trimethoprim-sulfamethoxazole.

Authors:  F O'Grady; I K Fry; A McSherry; W R Cattell
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

6.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

7.  The diffusion and concentration of trimethoprim in human vaginal fluid.

Authors:  T A Stamey; M Condy
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

8.  The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections.

Authors:  T A Stamey; C C Sexton
Journal:  J Urol       Date:  1975-02       Impact factor: 7.450

9.  Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection.

Authors:  W Brumfitt; R Pursell
Journal:  Br Med J       Date:  1972-06-17

10.  Trimethoprim resistance determined by R factors.

Authors:  M P Fleming; N Datta; R N Grüneberg
Journal:  Br Med J       Date:  1972-03-18
View more
  6 in total

1.  Risk factors for fecal colonization with trimethoprim-resistant and multiresistant Escherichia coli among children in day-care centers in Houston, Texas.

Authors:  R R Reves; M Fong; L K Pickering; A Bartlett; M Alvarez; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 2.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

3.  Resistance among fecal flora of patients taking sulfamethoxazole-trimethoprim or trimethoprim alone.

Authors:  R L Guerrant; S J Wood; L Krongaard; R A Reid; R H Hodge
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

4.  Emergence of trimethoprim resistance in fecal flora.

Authors:  P Huovinen; T Mattila; O Kiminki; L Pulkkinen; S Huovinen; M Koskela; R Sunila; P Toivanen
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 5.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

6.  Surveillance cultures and benefit of laminar airflow units in patients undergoing bone marrow transplantation.

Authors:  W Heizmann; G Ehninger; A Vallbracht; K Botzenhart
Journal:  Infection       Date:  1987       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.